Your search returned 9 results.

Results
	1.	Varespladib methyl in cardiovascular disease. [electronic resource] by Rosenson, Robert S Fraser, Heather Trias, Joaquim Hislop, Colin Producer: 20110216 In: Expert opinion on investigational drugs vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. [electronic resource] by Scheinberg, Morton A Hislop, Colin M Martin, Renee S Producer: 20161027 In: Expert opinion on biological therapy vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. [electronic resource] by Rosenson, Robert S Elliott, Michael Stasiv, Yuri Hislop, Colin Producer: 20120106 In: European heart journal vol. 32 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. [electronic resource] by Rosenson, Robert S Fraser, Heather Goulder, Michael A Hislop, Colin Producer: 20120327 In: Cardiovascular drugs and therapy vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy. [electronic resource] by Golmia, Andrea Pimentel Fonseca Martin, Renee Hislop, Colin Scheinberg, Morton Producer: 20140617 In: Rheumatology (Oxford, England) vol. 53 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. [electronic resource] by Rosenson, Robert S Hislop, Colin Elliott, Michael Stasiv, Yuri Goulder, Michael Waters, David Producer: 20101019 In: Journal of the American College of Cardiology vol. 56 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. [electronic resource] by Rosenson, Robert S Hislop, Colin McConnell, Daniel Elliott, Michael Stasiv, Yuri Wang, Nan Waters, David D Producer: 20090305 In: Lancet (London, England) vol. 373 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. [electronic resource] by Nicholls, Stephen J Cavender, Matthew A Kastelein, John J P Schwartz, Gregory Waters, David D Rosenson, Robert S Bash, Dianna Hislop, Colin Producer: 20120626 In: Cardiovascular drugs and therapy vol. 26 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. [electronic resource] by Fraser, Heather Hislop, Colin Christie, Robert M Rick, Heather L Reidy, Charles A Chouinard, Michael L Eacho, Patrick I Gould, Kenneth E Trias, Joaquim Producer: 20100920 In: Journal of cardiovascular pharmacology vol. 53 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)